Kezar Life Sciences Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$50M
Kezar Life Sciences General Information
Description
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
Contact Information
Website
www.kezarlifesciences.comCorporate Office
- 4000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 4000 Shoreline Court
- Suite 300
- South San Francisco, CA 94080
- United States
Kezar Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 11-May-2026 | $50M | Completed | Generating Revenue | ||
| 8. Merger/Acquisition | 08-Oct-2024 | Cancelled | Generating Revenue | |||
| 7. General Corporate Purpose | 10-Nov-2021 | Completed | Generating Revenue | |||
| 6. PIPE | 12-Feb-2021 | Completed | Generating Revenue | |||
| 5. PIPE | 14-Feb-2020 | Completed | Generating Revenue | |||
| 4. PIPE | 31-Mar-2019 | Completed | Generating Revenue | |||
| 3. IPO | 21-Jun-2018 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 25-Jul-2017 | $50M | $73M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 05-Jun-2015 | $23M | $23M | Completed | Startup |
Kezar Life Sciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Kezar Life Sciences Comparisons
Industry
Financing
Details
Kezar Life Sciences Competitors (67)
One of Kezar Life Sciences’s 67 competitors is Arvinas, a Formerly VC-backed company based in New Haven, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Lycia Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Praxis (Drug Discovery) | Formerly VC-backed | Boston, MA | ||||
| PharmAbcine | Corporate Backed or Acquired | Daejeon, South Korea |
Kezar Life Sciences Patents
Kezar Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026183140-A1 | Dosing regimens for zetomipzomib | Pending | 25-Feb-2025 | ||
| WO-2023164250-A1 | Sec61 inhibitors and use thereof | Inactive | 28-Feb-2022 | ||
| JP-2023539553-A | Protein secretion inhibitor | Pending | 31-Aug-2020 | ||
| AU-2021334388-A1 | Protein secretion inhibitors | Inactive | 31-Aug-2020 | ||
| CA-3190441-A1 | Protein secretion inhibitors | Pending | 31-Aug-2020 | C07D417/14 |
Kezar Life Sciences Signals
Kezar Life Sciences ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.49 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Kezar Life Sciences FAQs
-
When was Kezar Life Sciences founded?
Kezar Life Sciences was founded in 2015.
-
Where is Kezar Life Sciences headquartered?
Kezar Life Sciences is headquartered in South San Francisco, CA.
-
What is the size of Kezar Life Sciences?
Kezar Life Sciences has 9 total employees.
-
What industry is Kezar Life Sciences in?
Kezar Life Sciences’s primary industry is Drug Discovery.
-
Is Kezar Life Sciences a private or public company?
Kezar Life Sciences is a Private company.
-
What is the current valuation of Kezar Life Sciences?
The current valuation of Kezar Life Sciences is .
-
What is Kezar Life Sciences’s current revenue?
The current revenue for Kezar Life Sciences is .
-
How much funding has Kezar Life Sciences raised over time?
Kezar Life Sciences has raised $220M.
-
Who are Kezar Life Sciences’s competitors?
Arvinas, Sarepta Therapeutics, Lycia Therapeutics, Praxis (Drug Discovery), and PharmAbcine are some of the 67 competitors of Kezar Life Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process